MaxCyte, Inc. (MXCT) vs RxSight, Inc. (RXST)
- MaxCyte, Inc. MXCT 1.31 0.00%
- RxSight, Inc. RXST 4.52 −0.44%
MaxCyte, Inc. and RxSight, Inc. are both Medical Devices companies. RxSight, Inc. is the larger, with a market value of $190.4M against $135.2M — 1.4× the size. MaxCyte, Inc. grew revenue faster over the last twelve months: −13.2% against −14.3%. RxSight, Inc. has the higher net margin (−43.8% vs −114.8%) and the lower return on invested capital (−16,845.7% vs −49.2%). Across the 17 metrics below, RxSight, Inc. leads on 10 and MaxCyte, Inc. on 7.
Valuation
Profitability
| Metric | MXCT | RXST | Medical Devices median |
|---|---|---|---|
| Gross margin | 79.23% | 76.13% | 57.76% |
| Operating margin | (134.59%) | (50.44%) | (15.07%) |
| Net margin | (114.77%) | (43.80%) | (14.45%) |
| Free cash flow margin | (76.14%) | 15.30% | (3.88%) |
| Return on equity | (20.39%) | (20.10%) | (10.35%) |
| Return on assets | (17.62%) | (16.44%) | (17.26%) |
| Return on invested capital | (49.23%) | (16,845.67%) | (5.27%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack